RecruitingNot ApplicableNCT04434586

Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions


Sponsor

University Hospital, Lille

Enrollment

166 participants

Start Date

Jun 16, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

This is a common care study. A study for evaluating the quality of balloon inflation and stent application will be performed in 2D angiography alone in the control group and then by 2D and OCT angiography for the experimental group. The benefit could be an improvement in the results of revascularization of femoropopliteal lesions thanks to OCT which allows a 3D visualization of the arterial lumen.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patient over 18 years old
  • Femoral-popliteal lesion TASC-C or TASC-D de novo (F1 to P1)
  • Starting lesion on the superficial femoral artery and not extending beyond the intercondylar notch (P2)
  • ≥1 continuous permeable leg axis directly injecting the plantar arch
  • Rutherford 2-5

Exclusion Criteria8

  • Patient under personal protection regime (tutorship, guardianship)
  • Absence of arterial axis in permeable leg
  • Patient presenting a limb acute ischaemia (chart evolving since less than 14 days)
  • Patient without favorable element to consider healing
  • History of stents on the femoropopliteal axis
  • History of femoropopliteal bypass
  • Untreated stenosis ≥30% on the iliac axis and common femoral upstream
  • Popliteal lesion beyond the intercondylar notch (P2)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEfemoropopliteal revascularization for TASC C or TASC D lesion

Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control


Locations(1)

Insitut Coeur-Poumon, CHU

Lille, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04434586


Related Trials